Clinical trial
A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation
NCT02690519 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation
- Lead sponsor
- Lakefront Biotherapeutics NV
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- September 30, 2016
- Enrollment
- 7 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.